Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 2/2017

01.06.2017 | case report

Brentuximab vedotin in a patient with enteropathy-associated T‑cell lymphoma of the small bowel

verfasst von: MD Ferdinand Haslbauer

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

As the prognosis of enteropathy-associated T‑cell lymphoma is poor, innovative treatment options are called for, such as the anti-CD30 monoclonal antibody–drug conjugate brentuximab vedotin. The patient presented in this report was diagnosed with enteropathy-associated T‑cell lymphoma that affected the jejunum. Standard chemotherapy with CHOP induced complete remission, but the disease relapsed within 8 months, with the ileum as the site of relapse. Since further testing revealed CD30 positivity, treatment with brentuximab vedotin was started. After 18 cycles, the treatment had to be discontinued owing to another condition that required surgery, upon which the patient relapsed. However, resumption of brentuximab vedotin therapy restored partial remission within 3 months.
Literatur
1.
Zurück zum Zitat Okada M, Maeda K, Suzumiya J, et al. Primary colorectal T‑cell lymphoma. J Gastroenterol. 2003;38(3):376–84. CrossRefPubMed Okada M, Maeda K, Suzumiya J, et al. Primary colorectal T‑cell lymphoma. J Gastroenterol. 2003;38(3):376–84. CrossRefPubMed
2.
Zurück zum Zitat Zinzani PL, Magagnoli M, Pagliani G, et al. Primary intestinal lymphoma: clinical and therapeutic features of 32 patients. Haematologica. 1997;82(3):305–8. PubMed Zinzani PL, Magagnoli M, Pagliani G, et al. Primary intestinal lymphoma: clinical and therapeutic features of 32 patients. Haematologica. 1997;82(3):305–8. PubMed
3.
Zurück zum Zitat Swerdlow SH, Campo E, Harris NL. et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. Swerdlow SH, Campo E, Harris NL. et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
4.
Zurück zum Zitat Sieniawski MK, Lennard AL. Enteropathy-associated T‑cell lymphoma: epidemiology, clinical features, and current treatment strategies. Curr Hematol Malig Rep. 2011;6(4):231–40. CrossRefPubMed Sieniawski MK, Lennard AL. Enteropathy-associated T‑cell lymphoma: epidemiology, clinical features, and current treatment strategies. Curr Hematol Malig Rep. 2011;6(4):231–40. CrossRefPubMed
5.
Zurück zum Zitat Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90. CrossRefPubMedPubMedCentral Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90. CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Sieniawski M, Angamuthu N, Boyd K, et al. Evaluation of enteropathy-associated T‑cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010;115(18):3664–70. CrossRefPubMed Sieniawski M, Angamuthu N, Boyd K, et al. Evaluation of enteropathy-associated T‑cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010;115(18):3664–70. CrossRefPubMed
7.
Zurück zum Zitat Tse E, Gill H, Loong F, et al. Type II enteropathy-associated T‑cell lymphoma: a multicenter analysis from the Asia Lymphoma Study Group. Am J Hematol. 2012;87(7):663–8. CrossRefPubMed Tse E, Gill H, Loong F, et al. Type II enteropathy-associated T‑cell lymphoma: a multicenter analysis from the Asia Lymphoma Study Group. Am J Hematol. 2012;87(7):663–8. CrossRefPubMed
8.
Zurück zum Zitat Nijeboer P, Malamut G, Mulder CJ, et al. Enteropathy-associated T‑cell lymphoma: improving treatment strategies. Dig Dis. 2015;33:231–5. CrossRefPubMed Nijeboer P, Malamut G, Mulder CJ, et al. Enteropathy-associated T‑cell lymphoma: improving treatment strategies. Dig Dis. 2015;33:231–5. CrossRefPubMed
9.
Zurück zum Zitat Malamut G, Chandesris O, Verkarre V, et al. Enteropathy associated T‑cell lymphoma in celiac disease: a large retrospective study. Dig Liver Dis. 2013;45:377–84. CrossRefPubMed Malamut G, Chandesris O, Verkarre V, et al. Enteropathy associated T‑cell lymphoma in celiac disease: a large retrospective study. Dig Liver Dis. 2013;45:377–84. CrossRefPubMed
10.
Zurück zum Zitat Gale J, Simmonds PD, Mead GM, et al. Enteropathy-type intestinal T‑cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol. 2000;18:795–803. CrossRefPubMed Gale J, Simmonds PD, Mead GM, et al. Enteropathy-type intestinal T‑cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol. 2000;18:795–803. CrossRefPubMed
11.
Zurück zum Zitat Jantunen E, Boumendil A, Finel H, et al. Autologous stem cell transplantation for enteropathy-associated T‑cell lymphoma: a retrospective study by the EBMT. Blood. 2013;121:2529–32. CrossRefPubMed Jantunen E, Boumendil A, Finel H, et al. Autologous stem cell transplantation for enteropathy-associated T‑cell lymphoma: a retrospective study by the EBMT. Blood. 2013;121:2529–32. CrossRefPubMed
12.
Zurück zum Zitat d’Amore F, Relander T, Lauritzsen GF, et al. Upfront autologous stem-cell transplantation in peripheral T‑cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–9. CrossRefPubMed d’Amore F, Relander T, Lauritzsen GF, et al. Upfront autologous stem-cell transplantation in peripheral T‑cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–9. CrossRefPubMed
13.
Zurück zum Zitat Delabie J, Holte H, Vose JM, et al. Enteropathy-associated T‑cell lymphoma: clinical and histological findings from the International Peripheral T‑Cell Lymphoma Project. Blood. 2011;118(1):148–55. CrossRefPubMed Delabie J, Holte H, Vose JM, et al. Enteropathy-associated T‑cell lymphoma: clinical and histological findings from the International Peripheral T‑Cell Lymphoma Project. Blood. 2011;118(1):148–55. CrossRefPubMed
15.
Zurück zum Zitat Khalaf WF, Caldwell ME, Reddy N. Brentuximab in the treatment of CD30-positive enteropathy-associated T‑cell lymphoma. J Natl Compr Canc Netw. 2013;11:137–40. CrossRefPubMed Khalaf WF, Caldwell ME, Reddy N. Brentuximab in the treatment of CD30-positive enteropathy-associated T‑cell lymphoma. J Natl Compr Canc Netw. 2013;11:137–40. CrossRefPubMed
16.
Zurück zum Zitat Zelenetz AD, Abramson JS, Advani RH. et al. NCCN Clinical Practice Guidelines in oncology for Non-Hodgkin’s lymphomas. Version 1.2013 2013. NCCN.org. Accessed 16 January 2013. Zelenetz AD, Abramson JS, Advani RH. et al. NCCN Clinical Practice Guidelines in oncology for Non-Hodgkin’s lymphomas. Version 1.2013 2013. NCCN.org. Accessed 16 January 2013.
17.
Zurück zum Zitat Grigg-Gutierrez NM, Estremera-Marcial R, Caceres WW, Toro DH. Primary enteropathy-associated T‑cell lymphoma type 2: an emerging entity? Cancer Control. 2015;22(2):242–7. PubMed Grigg-Gutierrez NM, Estremera-Marcial R, Caceres WW, Toro DH. Primary enteropathy-associated T‑cell lymphoma type 2: an emerging entity? Cancer Control. 2015;22(2):242–7. PubMed
18.
Zurück zum Zitat Nijeboer P, Malamut G, Mulder CJ, et al. Enteropathy-associated T‑cell lymphoma: improving treatment strategies. Dig Dis. 2015;33(2):231–5. CrossRefPubMed Nijeboer P, Malamut G, Mulder CJ, et al. Enteropathy-associated T‑cell lymphoma: improving treatment strategies. Dig Dis. 2015;33(2):231–5. CrossRefPubMed
Metadaten
Titel
Brentuximab vedotin in a patient with enteropathy-associated T‑cell lymphoma of the small bowel
verfasst von
MD Ferdinand Haslbauer
Publikationsdatum
01.06.2017
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2017
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-017-0312-x

Weitere Artikel der Ausgabe 2/2017

memo - Magazine of European Medical Oncology 2/2017 Zur Ausgabe